Leveraging PCSK9-Targeting Therapies in Hyperlipidemia Management to Reduce Cardiovascular Risks

Chair, Norman E. Lepor, MD, FACC, FAHA, FSCAI, discusses hyperlipidemia in this CME activity titled “Envisioning the Future of Hyperlipidemia Management: How Can We Leverage PCSK9-Targeting Therapies to Prevent Primary and Secondary Cardiovascular Events?” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at PeerView.com/TVJ865. CME credit will be available until September 28, 2023.
Be the first to comment